L.P. Ra Capital Management Adds ARS Pharmaceuticals Shares
L.P. Ra Capital Management acquired 30,000 shares of ARS Pharmaceuticals on June 24, 2026.
Key Points
- L.P. Ra Capital Management bought 30,000 shares of ARS Pharmaceuticals on June 24, 2026, with shares trading near $8.54 on Saturday.
- ARS Pharmaceuticals, with a market cap of $796.4 million, has a 52-week range of $6.66 to $18.9 and a forward P/E of -8.38.
- Recent insider activity includes purchases by L.P. Ra Capital Management and sales by Eric Karas, Chief Commercial Officer.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
L.P. Ra Capital Management recently acquired 30,000 shares of ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY) on June 24, 2026. This insider purchase reflects ongoing interest in the company, with shares trading near $8.54 on Saturday.
Insider Buying and Selling at ARS Pharmaceuticals, Inc.
On June 24, 2026, L.P. Ra Capital Management purchased 30,000 shares of ARS Pharmaceuticals. This transaction was not part of a pre-planned trading scheme. Additionally, Rajeev Dadoo also bought 30,000 shares on the same day. Earlier in June, Eric Karas, the Chief Commercial Officer, sold 25,000 shares at an average price of $10.00 under a Rule 10b5-1 plan, but also purchased 25,000 shares at $1.50.
ARS Pharmaceuticals, Inc. Stock Up 45.0%
Shares of ARS Pharmaceuticals traded near $8.54 on Saturday. The company has a market cap of approximately $796.4 million. ARS Pharmaceuticals is not currently profitable, with a forward P/E ratio of -8.38. Its 52-week range is between $6.66 and $18.9. The stock's 50-day moving average is $8.69, and the 200-day moving average is $9.37. The firm's current ratio stands at 4.94, with a quick ratio of 4.65 and a debt-to-equity ratio of 279.24.
$SPRY stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 25, 2026, Leerink Partners maintained a 'buy' rating on ARS Pharmaceuticals with a price target of $24.0. Cantor Fitzgerald also maintained its 'buy' rating with a target of $30.0 on May 28, 2026. The consensus among analysts is a 'strong buy' with a mean target price of $28.4, based on five analyst opinions.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., headquartered in San Diego, California, is a biopharmaceutical company focused on developing treatments for severe allergic reactions. Its primary product, neffy, is a needle-free intranasal delivery system for epinephrine, targeting emergency treatment for Type I allergic reactions, including anaphylaxis. Founded in 2015, the company operates in the biotechnology sector and employs 154 people under the leadership of CEO Richard E. Lowenthal.
Bottom Line
The recent insider buying by L.P. Ra Capital Management suggests confidence in ARS Pharmaceuticals' prospects. Investors follow insider transactions as a possible indicator of a company's outlook. It's important to remember that these filings reflect past activity and might not represent current holdings.
Get ARS Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SPRY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.